oral hypoglycemic agent

Introduction

Hypoglycemic agents taken by mouth.

Indications

• treatment of diabetes mellitus type 2

Adverse effects

• hypoglycemia*
• hepatotoxicity
  • thiazolidinediones least associated with hepatocellular carcinoma
  • GLP-1 receptor agonist least associated with hepatic decompensation, variceal bleeding & hepatic encephalopathy
  • SGLT2 inhibitors were least associated with cirrhosis 7 liver-related mortality

* hypoglycemic agents least likely to cause hypoglycemia

• metformin
• SGLT2 inhibitors (flozins)
• GLP-1 receptor agonists (incretin mimetics, glutides)
• tirzepatide
• thiazolidinediones (glitazones)
• dipeptidyl peptidase-4 inhibitors (gliptins)

• drug adverse effects of hypoglycemic agents

Laboratory

• hypoglycemics.oral in hair
• hypoglycemics.oral in body fluid
  • hypoglycemics.oral in blood
  • hypoglycemics.oral in serum/plasma
  • hypoglycemics.oral in urine

More general terms

• hypoglycemic agent

More specific terms

• alpha glucosidase inhibitor
• gliptin; dipeptidyl peptidase-4 inhibitor; DPP-4 inhibitor
• glitazar
• meglitinide (Meglitinido, Meglitinidum)
• metformin (Glucophage)
• oral insulin
• SGLT-2 inhibitor; oral glucosuric agent; flozin
• sulfonylurea
• thiazolidinedione; glitazone; TZD